Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients
The objective of this Phase I/II pilot study is to evaluate the safety and effectiveness of a non- antibiotic chelator based lock solution that contains nitroglycerin in combination with sodium citrate and ethanol (NiCE lock solution) for prevention of central line associated bloodstream infection (CLABSI).
The primary objective of this study is to evaluate the safety and estimate the rate of adverse events associated with the NiCE lock solution.
The second primary objective is to estimate the rate of CLABSI in patients receiving the NiCE lock solution.
100 Clinical Results associated with Novel Anti-Infective Technologies, LLC
0 Patents (Medical) associated with Novel Anti-Infective Technologies, LLC
100 Deals associated with Novel Anti-Infective Technologies, LLC
100 Translational Medicine associated with Novel Anti-Infective Technologies, LLC